Advanced CT and Robotics Company, Epica International, Closes Financing Round With Partners for Growth Fund V
NEW YORK, Aug. 31, 2017 /PRNewswire/ -- Epica International, Inc. ("Epica"), a leading robotic CT company headquartered in San Clemente, California, recently announced the closing of a financing round with the investment group, Partners for Growth ("PFG"). PFG structured the $5 million term-debt facility in this capital raise, providing growth capital to support Epica's expansion into new markets across both imaging and robotics.
Epica was assisted by the NYC management consultancy, Facilitated Growth, LLC, which acted as the key advisor on this deal, assisting in the diligence process for Epica's subsidiaries; a non-invasive CT medical imaging company, a robotics company, an advanced R&D technology center, and two commercial sales and marketing groups.
The funds are earmarked for use on growing operations, increasing the sales force, and preparing for entry into the human medical market. "This infusion of capital will assist us in furthering our goals to integrate CT imagery with precision robotics and ultimately deliver the future of medical diagnosis and therapy," said Epica CEO, Frank D'Amelio.
The Annual General Meeting of Bioretec Ltd was held on 26 April 2024 in Tampere, Finland.
The Annual General Meeting approved the financial statements for the financial year 1 January?31 December 2023 and resolved to discharge the members of the...
IDEAYA Biosciences, Inc. , a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on April 25, 2024, the Compensation Committee of IDEAYA's Board of Directors granted...
-- Diluted EPS of $2.16; Adjusted Diluted EPS of $2.26 ---- Increases 2024 Full Year Guidance --
2024 adjusted diluted EPS of $2.26, up over 7% from $2.11 in the first quarter of 2023.Increases 2024 full year adjusted diluted EPS guidance by $0.10 to...
Avantor, Inc. , a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its first...
Swedish Orphan Biovitrum AB (publ) (Sobi®) has established a medium term note programme with a framework amount of SEK 10 billion or the equivalent thereof in EUR (the "MTN Programme").
For this purpose, Sobi has prepared a base prospectus, which...
OMRON Healthcare Co., Ltd. based in Muko, Kyoto Prefecture, Japan, announces to be the official sponsor of May Measurement Month (MMM,) a global campaign to raise awareness of blood pressure screening and promote hypertension prevention, detection,...
